Genetraks raises $6m
Wednesday, 18 December, 2002
Genetraks, a start-up biotech developing blood tests for use in pre-race evaluation of animals such as racehorses, has received a $6 million injection of venture capital.
The commercial potential of its technology for assessing the health of racing animals with a view to maximising their performance has helped the company win investment interest in a difficult market.
The Brisbane company, which received earlier support from St George Innovation Fund and a $246,380 Biotechnology Innovation Fund (BIF) grant, is based on bioinformatics techniques. Its technology relates to the diagnostic capacity of gene expression 'signatures' in white blood cells in immune-mediated diseases.
The company is led by two veterinary PhDs, Rosalyn and Richard Brandon, who respectively are its CEO and biotechnology director.
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
